Suspicious axillary nodes remain after dissection in nearly half of high-risk breast cancer patients

In 152 clinically node-positive breast cancer patients, 47.4% retained initially suspicious axillary nodes after dissection, with limited regional recurrence following RT.

KEY POINTS

  • This retrospective single-center study from Technical University of Munich, Germany, evaluated 152 patients with clinically node-positive breast cancer who underwent axillary lymph node dissection (ALND) followed by adjuvant radiotherapy between 2019 and 2024. Three breast imaging radiologists systematically compared pretreatment staging CT with postoperative planning CT to identify initially suspicious lymph nodes that remained visible following surgery. ALND was performed at six hospitals by 39 surgeons, with a median of 11 nodes removed per patient.
  • Residual initially suspicious axillary lymph nodes were identified in 72/152 patients (47.4%). Among affected patients, the median number of residual suspicious nodes was two (range 1–15), compared with a median of six initially suspicious nodes (range 1–33). Most residual nodes were located in axillary level I (53.7%) or level II (36.1%), with fewer in levels III and IV. These were imaging-identified nodes considered suspicious before treatment, not pathologically confirmed residual metastatic deposits.
  • Initial nodal disease burden predicted the presence of residual suspicious nodes. Each additional initially suspicious node was associated with greater odds of postoperative residual suspicious nodes (OR 1.27, 95% CI 1.12–1.43; p<0.001). The number of pathologically positive dissected nodes was also associated with residual nodes (OR 1.35, 95% CI 1.04–1.75; p=0.022). In contrast, the total number of surgically removed nodes was not associated with their presence (p=0.715).
  • Adjuvant radiotherapy provided substantial incidental or intentional exposure to the residual-node regions. Regional nodal irradiation was delivered in 151/152 patients (99.3%), predominantly using VMAT, with a median total prescription of 50.4 Gy. Among patients with residual suspicious nodes, level III/IV was intentionally irradiated in 98.6%, level II in 94.4%, and level I in 61.1%. Among patients without intentional level I irradiation, 78.5% received a mean level I dose of at least 85% of the prescribed dose.
  • Regional axillary recurrence was uncommon during available follow-up. After median follow-up of 30 months, one patient (1.4%) with residual suspicious nodes developed regional axillary recurrence, while three (4.2%) developed local recurrence. No local or regional recurrence was observed in patients without residual suspicious nodes. However, the small number of events prevents reliable conclusions about the adequacy of specific nodal doses or the clinical significance of residual radiological findings.
  • Distant metastases were more frequent among patients with residual suspicious nodes before accounting for baseline disease burden. Distant metastases occurred in 16.6% versus 5.0%, respectively (OR 3.66, 95% CI 1.12–11.95; p=0.032). After stratifying by the number of initially suspicious nodes, the difference was no longer statistically significant. This suggests that residual suspicious nodes may largely reflect greater initial nodal tumor burden rather than an independent predictor of metastatic spread.
  • The study does not establish that irradiation eliminates residual axillary disease. Residual nodes were not routinely biopsied after systemic treatment or surgery, and radiological persistence does not prove viable malignancy. The cohort lacked a nonirradiated comparison group, while radiation-field selection and nodal coverage were individualized. Consequently, low regional failure rates cannot be attributed specifically to incidental axillary dose or used to define an optimal postdissection treatment volume.

CLINICAL TAKEAWAY

Initially suspicious axillary lymph nodes may remain visible after ALND in patients with high initial nodal burden, particularly in levels I and II. Comparing pretreatment staging imaging with postoperative planning CT may help identify regions warranting closer review during adjuvant breast radiotherapy planning. However, pathological significance and the independent benefit of irradiating these nodes remain uncertain.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction